Should you buy Iovance Biotherapeutics stock now?
Yes, the technical signal for Iovance Biotherapeutics is currently BUY. Iovance Biotherapeutics trades at $5.88 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.029 with falling momentum (signal: 0.124); RSI is at 46.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $8.22 points to 39.8% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Iovance Biotherapeutics stock?
The average analyst price target for Iovance Biotherapeutics is $8.22. The current price is $5.88, which gives an upside of 39.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $7.40 and $9.04.
Is Iovance Biotherapeutics a dividend stock?
No, Iovance Biotherapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Iovance Biotherapeutics stock?
Iovance Biotherapeutics is rated as a stock with extreme risk. the annual standard deviation is 93.6%, which classifies the stock as extreme risk.
Is Iovance Biotherapeutics overvalued?
No, Iovance Biotherapeutics is considered undervalued based on the analyst price target (39.8% upside). Iovance Biotherapeutics has the following valuation ratios: a P/S ratio of 6.8, a P/B ratio of 2.5. The analyst price target suggests that the stock is undervalued by 39.8%.
Is Iovance Biotherapeutics overbought?
No, Iovance Biotherapeutics is not overbought. RSI is at 46.8 (neutral zone). The technical indicators show: RSI is at 46.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 26.9% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Iovance Biotherapeutics earnings report?
Iovance Biotherapeutics reports earnings TODAY, August 6, 2026! The stock currently trades at $5.88. Watch how the price reacts after the release.
Is Iovance Biotherapeutics shorted?
Yes, Iovance Biotherapeutics is shorted with 24.0% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Iovance Biotherapeutics stock?
No, insiders are not buying Iovance Biotherapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 9 sales. On a net basis, 466,781 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 2,110,891 $ sold. Active sellers include Vogt Frederick G, Puri Raj K., GRAF FINCKENSTEIN FRIEDRICH and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Iovance Biotherapeutics a good stock?
Based on our total score, Iovance Biotherapeutics is rated as a poor stock with a total score of 32 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 21/100, Quality: 3/100, Momentum: 73/100. In addition: analysts see 39.8% upside to the price target; technical signal: Strong Buy. Whether Iovance Biotherapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Iovance Biotherapeutics stock?
The outlook for Iovance Biotherapeutics based on current data: the average analyst price target is $8.22 (+39.8%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Iovance Biotherapeutics stock rising?
Iovance Biotherapeutics is rising right now. The technical indicators show: the price is 26.9% above the 20-day average; short interest is 24.0% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Iovance Biotherapeutics go?
The average analyst price target for Iovance Biotherapeutics is $8.22, which corresponds to a potential gain of 39.8% from the current price of $5.88. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Iovance Biotherapeutics fall?
We lack enough history to give a specific floor for Iovance Biotherapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Iovance Biotherapeutics do?
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationall... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Iovance Biotherapeutics as an investment.
Did Iovance Biotherapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Iovance Biotherapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Iovance Biotherapeutics making money or losing money?
No, Iovance Biotherapeutics is currently not making money — the company is losing money with a negative profit margin of -123.9%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Iovance Biotherapeutics go bankrupt?
The bankruptcy risk of Iovance Biotherapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -6.52 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 28% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Iovance Biotherapeutics have a lot of debt?
No, Iovance Biotherapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 28%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
